title: BMS-275291. Bristol-Myers Squibb.
abstract: Bristol-Myers Squibb (BMS) is developing BMS-275291, which is a matrix metalloproteinase (MMP) inhibitor, for the potential treatment of cancer. It was originally developed by Chiroscience R&D (now known as Celltech Group plc), and it inhibits a broad range of MMPs known to be associated with the growth and spread of tumors. Advantageously, it does not inhibit MMP-mediated shedding events, which may be involved in the side effects associated withfirst-generation MMP inhibitors. ByMarch 2001, BMS-275291 was undergoing phase II/III trials, as an adjunct to standard chemotherapy, involving non-small cell lung cancer patients. In March 1999, Lehman Brothers predicted that the compound had a 25% chance of reaching the market, with a possible launch anticipated in 2005 and potential peak sales of $500 million in 2010. In November 2000, Lehman Brothers revised their predictions estimating a 2004 launch with a 20% chance of reaching the market; predicted peak sales were unchanged. In January 2002, Morgan Stanley Dean Witter expressed the view that release of positive phase II/III trials data would surprise stock markets.
authors.affiliation: Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston 02114, USA. poulakiv@hotmail.com
authors.forename: Vassiliki
authors.initials: V
authors.lastname: Poulaki
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D000075202:Contraindications; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D006801:Humans; D007093:Imidazoles; D061965:Matrix Metalloproteinase Inhibitors; D009369:Neoplasms / Q000188:drug therapy*; D009930:Organic Chemicals; D013329:Structure-Activity Relationship
chemical_list: D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D007093:Imidazoles; D061965:Matrix Metalloproteinase Inhibitors; D009930:Organic Chemicals; C422302:N-((2S)-2-mercapto-1-oxo-4-(3,4,4- trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3- dimethyl-L-Valinamide